Secretagogin is increased in plasma from type 2 diabetes patients and potentially reflects stress and islet dysfunction.

ABSTRACT: Beta cell dysfunction accompanies and drives the progression of type 2 diabetes mellitus (T2D), but there are few clinical biomarkers available to assess islet cell stress in humans. Secretagogin, a protein enriched in pancreatic islets, demonstrates protective effects on beta cell function in animals. However, its potential as a circulating biomarker released from human beta cells and islets has not been studied. In this study primary human islets, beta cells and plasma samples were used to explore secretion and expression of secretagogin in relation to the T2D pathology. Secretagogin was abundantly and specifically expressed and secreted from human islets. Furthermore, T2D patients had an elevated plasma level of secretagogin compared with matched healthy controls, which was confirmed in

SUBMITTER: Hansson SF 

PROVIDER: S-EPMC5922551 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature